A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies (Q34477833)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies |
scientific article |
Statements
1 reference
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies (English)
1 reference
Susan M Perkins
1 reference
Matthew A Gubens
1 reference
Matthew Burns
1 reference
Melanie San Pedro-Salcedo
1 reference
Sandy K Althouse
1 reference
Patrick J Loehrer
1 reference
Heather A Wakelee
1 reference
25 April 2015
1 reference
1 reference
89
1 reference
1
1 reference
57-60
1 reference
Identifiers
1 reference
1 reference